Skip to content

A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients

A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients - A prospective observational study of ultra-hypofractionated radiotherapy for postoperative breast cancer patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000054077
Enrollment
30
Registered
2024-04-05
Start date
2024-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Sponsors

Juntendo University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients must be at least 20 years old at the time of consent (no upper age limit). Patients scheduled for postoperative irradiation as breast-conserving??therapy. Patients who have been thoroughly informed about their participation in this study and have provided written consent of their own free will based on adequate understanding.

Exclusion criteria

Exclusion criteria: Patients with infections that require systemic treatment. Pregnant, possibly pregnant, or lactating patients. Patients who have previously received chest radiation therapy. Patients are scheduled for concurrent chemotherapy. Patients with diabetes mellitus who are being treated with continuous insulin injections or are poorly controlled. Patients diagnosed with interstitial pneumonia, pulmonary fibrosis, or severe emphysema. Patients receive continuous systemic administration (oral or intravenous) of steroids. Patients receiving immunosuppressive agents for active collagen disease Patients with severe cardiac disease or heart failure. Patients who are deemed ineligible for participation in this study by the principal investigator or principal investigator-designated physicians.

Design outcomes

Primary

MeasureTime frame
Adverse events at 1, 3, and 6 months after the start of radiation therapy

Countries

Japan

Contacts

Public ContactNoriyuki Okonogi

Juntendo University Department of Radiation Oncology

n.okonogi.rd@juntendo.ac.jp03-5802-1230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026